Clinical manifestations and treatment of mucopolysaccharidosis type I patients in Latin America as compared with the rest of the world (Q35214507)

7 August 2017

Clinical manifestations and treatment of mucopolysaccharidosis type I patients in Latin America as compared with the rest of the world (English)

1 reference

7 August 2017

mucopolysaccharidosis I

1 reference

inferred from title

author name string

María Verónica Muñoz-Rojas

1

1 reference

7 August 2017

Luisa Bay

2

1 reference

7 August 2017

Luz Sanchez

3

1 reference

7 August 2017

Marcel van Kuijck

4

1 reference

7 August 2017

Sandra Ospina

5

1 reference

7 August 2017

Juan Francisco Cabello

6

1 reference

7 August 2017

Ana Maria Martins

7

1 reference

7 August 2017

4 May 2011

1 reference

Journal of Inherited Metabolic Disease

7 August 2017

1 reference

7 August 2017

34

1 reference

7 August 2017

5

1 reference

7 August 2017

1029-1037

1 reference

https://scigraph.springernature.com/pub.10.1007/s10545-011-9336-2

7 August 2017

0 references

cites work

Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173625

Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173625

Guidelines for the management of mucopolysaccharidosis type I.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173625

Mucopolysaccharidosis I: management and treatment guidelines

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173625

The clinical outcome of Hurler syndrome after stem cell transplantation.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173625

Sanfilippo syndrome: a mini-review

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173625

Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173625

The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173625

Laronidase treatment of mucopolysaccharidosis I.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173625

Cord-blood transplants from unrelated donors in patients with Hurler's syndrome

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173625

Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173625

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

13 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9336-2

Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9336-2

Enzyme-replacement therapy in mucopolysaccharidosis I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9336-2

A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9336-2

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9336-2

Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome

21 January 2018

1 reference

12 December 2020

Analysis of factors affecting development of carpal tunnel syndrome in patients with Hurler syndrome after hematopoietic cell transplantation

1 reference

12 December 2020

The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I

1 reference

12 December 2020

Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure

1 reference

12 December 2020

Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up

1 reference

12 December 2020

10.1007/S10545-011-9336-2

Identifiers

DOI

1 reference

7 August 2017

1 reference

7 August 2017

1 reference